# US 2026/0090879 A1 · Heart valve prostheses with a drug eluting mechanism

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090879 A1
- Document ID: US20260090879A1
- Status: Published application
- Kind: A1
- Application number: 19/110,415
- Filed: 2023-09-13
- Published: 2026-04-02
- Earliest claimed: 2022-09-13
- Assignees: National University of Singapore; National University Hospital (Singapore) Pte Ltd
- Applicants: National University of Singapore; National University Hospital (Singapore) Pte Ltd
- Inventors: Theodoros KOFIDIS
- Web page: https://patentgrep.com/patent/US20260090879A1

## CPC

- A61F 2/2409: {Support rings therefor, e.g. for connecting valves to tissue (annuloplasty rings A61F2/2442)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61F 2/2415: {Manufacturing methods}
- A61F 2/2418: {Scaffolds therefor, e.g. support stents}
- A61F 2/2445: {Annuloplasty rings in direct contact with the valve annulus}
- A61F 2/2448: {D-shaped rings}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/43: Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/65: Tetracyclines
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61F 2220/0075: sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
- A61F 2250/0067: Means for introducing or releasing pharmaceutical products into the body
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.

## Claims

### Claim 1

A heart valve prosthesis comprising one or more drug eluting mechanism, wherein said one or more drug eluting mechanism is embedded in the heart valve prosthesis during the manufacture of said heart valve prosthesis.

### Claim 2

A heart valve prosthesis comprising one or more drug eluting mechanism, wherein said one or more drug eluting mechanism is coated onto the heart valve prosthesis during the manufacture of said heart valve prosthesis.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The heart valve prosthesis according to claim 1, wherein said one or more drug eluting mechanism is a slow release, a fast release or a combination of slow and fast release mechanism.

### Claim 5 (depends on 1)

The heart valve prosthesis according to claim 1, wherein the one or more drug eluting mechanism comprises a drug exhibiting one or more effects selected from the group consisting of antibiotics, anti-calcification, antioxidant, anti-pannus, anti-fibrotic, antiproliferation and combinations thereof.

### Claim 6 (depends on 5)

The heart valve prosthesis according to claim 5, wherein the antiproliferative drug is selected from the group consisting of Sirolimus, Everolimus, Zotarolimus, Biolimus A9, Ridaforolimus, Tacrolimus, Paclitaxel, and Dexamethasone.

### Claim 7 (depends on 5)

The heart valve prosthesis according to claim 5, wherein the antibiotics is selected from the group consisting of Penicillin, Cephalosporin, Tetracyclines, Chloramphenicol, Macrolide antibiotics, Lincomines, Aminoglycoside Antibiotics, Polypeptide Antibiotics, Dichloropyridine, Quinolones, Factor XIa and Plasma Kallikrein (PKa) inhibitors.

### Claim 8 (depends on 2)

The heart valve prosthesis according to claim 2, wherein the heart valve prosthesis is a mechanical prosthesis, and the one or more drug eluting mechanism is coated on a strengthening ring or cuff of the mechanical prosthesis.

### Claim 9 (depends on 1)

The heart valve prosthesis according to claim 1, wherein the heart valve prosthesis is a mechanical prosthesis, and the one or more drug eluting mechanism is embedded under a cuff of the mechanical prosthesis.

### Claim 10 (depends on 9)

The heart valve prosthesis according to claim 9, wherein the one or more drug eluting mechanism comprises a drug loaded hydrogel.

### Claim 11 (depends on 10)

The heart valve prosthesis according to claim 10, wherein the drug loaded hydrogel is formed by (i) injection into a mold of a predesigned shape and (ii) UV crosslinking.

### Claim 12 (depends on 11)

The heart valve prosthesis according to claim 11, wherein the predesigned shape is an annulus ring, and the annulus ring shaped drug loaded hydrogel is configured to be sewn under a cuff of the mechanical prosthesis.

### Claim 13 (depends on 10)

The heart valve prosthesis according to claim 10, wherein the drug loaded hydrogel comprises drug loaded nanoparticles.

### Claim 14 (depends on 13)

The heart valve prosthesis according to claim 13, wherein the drug loaded nanoparticles are Sirolimus-loaded nanoparticles.

### Claim 15 (depends on 10)

The heart valve prosthesis according to any claim 10, wherein the one or more drug eluting mechanism comprises nanoparticles, wherein the nanoparticles are liposomes.

### Claim 16 (depends on 15)

The drug eluting mechanism according to claim 15, wherein the liposomes are composed of Egg Phosphatidylcholine (EggPC), POPC, POPG, DSPC, or any combination thereof.

### Claim 17 (depends on 9)

The heart valve prosthesis according to claim 9, wherein concentration of the drug in the drug eluting mechanism is of a minimum concentration of 80 nM in a total volume of 2 mL of cell culture media.

### Claim 18 (depends on 2)

The heart valve prosthesis according to claim 2, wherein the heart valve prosthesis is a bio-prosthesis, the one or more drug eluting mechanism is coated on frames or cuff of the bio-prosthesis.

### Claim 19 (depends on 1)

The heart valve prosthesis according to claim 1, wherein the heart valve prosthesis is a bio-prosthesis, the one or more drug eluting mechanism is embedded under fabric cuff of the bio-prosthesis.

### Claim 20 (depends on 2)

The heart valve prosthesis according to claim 2, wherein the heart valve prosthesis is a transcatheter valve prosthesis, the one or more drug eluting mechanism is coated on frames, cuff or leaflet of the transcatheter valve prosthesis.

### Claim 21

A heart repair ring comprising one or more drug eluting mechanism, wherein said one or more drug eluting mechanism is embedded in the heart repair ring during the manufacture of said heart repair ring.

### Claim at position 22

22-32. (canceled)
